市場調査レポート
商品コード
1497579
犬アトピー性皮膚炎市場:製品、アレルゲン、投与経路、流通チャネル、エンドユーザー別- 世界予測2024-2030年Canine Atopic Dermatitis Market by Product (Antihistamines, Glucocorticoids, Immunosuppressants), Allergen (Dander, Microorganisms, Mites), Route of Administration, Distribution Channel, End-User - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
犬アトピー性皮膚炎市場:製品、アレルゲン、投与経路、流通チャネル、エンドユーザー別- 世界予測2024-2030年 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
|
犬アトピー性皮膚炎市場規模は2023年に15億7,000万米ドルと推計され、2024年には16億9,000万米ドルに達し、CAGR 8.40%で2030年には27億6,000万米ドルに達すると予測されています。
犬アトピー性皮膚炎(CAD)は、異常な免疫反応や環境アレルゲンに対する先天的な素因による、犬の慢性的なそう痒性炎症性皮膚疾患です。ライフスタイルの変化に伴う犬の飼育率の増加や、ペットの健康管理に対する意識の高まりにより、世界中でCADの治療が行われるようになった。近年、診断技術の進歩により、この慢性疾患に対する効果的な治療法が確立されつつあります。しかし、診断や長期管理に伴う高額な費用が飼い主の障壁となり、新たな治療や療法の導入が制限されることもあります。犬アトピー性皮膚炎市場では、規制上のハードルが新規治療薬の開発と認可の妨げになる可能性があります。企業は、多様なCAD治療の商業化を確実にするため、変化する規制の知識を確保しながら、費用対効果の高い治療を提供する革新的な調査に取り組んでいます。次世代シークエンシング(NGS)などの新たな技術は、犬アトピー性皮膚炎の感受性や治療反応性に寄与する遺伝的要因を特定するのに役立ち、個別化治療のアプローチに貴重な情報を提供します。
主な市場の統計 | |
---|---|
基準年[2023] | 15億7,000万米ドル |
予測年[2024] | 16億9,000万米ドル |
予測年 [2030] | 27億6,000万米ドル |
CAGR(%) | 8.40% |
地域別インサイト
南北アメリカのCAD市場は、獣医学における大きな市場開拓と、新世代の治療法を提供するための既存企業による継続的な研究活動により、進展しています。米国とカナダでは、CADがペットのQOLに与える影響を認識する飼い主が増えており、同地域では効果的な治療に対する需要が急増しています。CADの有病率はアジア諸国、特に都市化した地域で著しく上昇しています。しかし、獣医皮膚科学に関する認知度は低く、市場構造も断片的であるため、この地域に進出する企業にとっては課題となっています。大手世界企業はアジアで存在感を示しているが、CAD治療に費用対効果の高い選択肢を提供する地元の中小メーカーと競合する必要があります。欧州市場は動物用皮膚科の成熟した市場であり、CADを管理するための専門的な診断ツールや治療ソリューションを提供する老舗企業によって特徴づけられています。大手製薬企業間の提携により、アトピー性皮膚炎に伴うそう痒症を緩和する画期的なモノクローナル抗体療法が開発されています。
FPNVポジショニングマトリックス
FPNVポジショニングマトリックスは、犬アトピー性皮膚炎市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、犬アトピー性皮膚炎市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、犬アトピー性皮膚炎市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[190 Pages Report] The Canine Atopic Dermatitis Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.69 billion in 2024, at a CAGR 8.40% to reach USD 2.76 billion by 2030.
Canine atopic dermatitis (CAD) is a chronic, pruritic inflammatory skin condition in dogs due to an inherited predisposition to aberrant immune responses and environmental allergens. Increasing dog ownership rates with changing lifestyles and greater awareness about pet healthcare have led to the adoption of CAD treatments worldwide. Recent years have observed advancements in diagnostic techniques, enabling effective treatment solutions for this chronic condition. However, high costs associated with diagnostics and long-term management can also be a barrier for pet owners, limiting the adoption of new treatments and therapies. Regulatory hurdles can impede the development and approval of novel therapeutics in the canine atopic dermatitis market. Companies are working on innovative research to offer cost-effective treatments while ensuring knowledge of the changing regulations to ensure the commercialization of diverse CAD treatments. Emerging technologies such as next-generation sequencing (NGS) could help identify genetic factors contributing to canine atopic dermatitis susceptibility or treatment response, providing valuable information for personalized therapy approaches.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.57 billion |
Estimated Year [2024] | USD 1.69 billion |
Forecast Year [2030] | USD 2.76 billion |
CAGR (%) | 8.40% |
Regional Insights
The Americas CAD market is advancing, driven by huge developments in veterinary medicine and ongoing research activities by established companies to offer new-generation treatments. With an increasing number of pet owners becoming aware of CAD's impact on their pets' quality of life in the U.S. and Canada, demand for effective treatments has surged in the region. The prevalence of CAD is significantly rising across Asian countries, particularly in urbanized regions. However, limited awareness about veterinary dermatology and fragmented market structures present challenges to companies catering to this region. Major global players have established a presence in Asia; however they need to contend with smaller local manufacturers that offer cost-effective alternatives for CAD treatments. The European market presents a mature landscape for veterinary dermatology, characterized by well-established companies offering specialized diagnostic tools and therapeutic solutions for managing CAD. Partnerships between leading pharmaceutical firms have led to the development of innovative monoclonal antibody therapies, which offer targeted relief from pruritus associated with atopic dermatitis.
Market Insights
The market dynamics represent an ever-changing landscape of the Canine Atopic Dermatitis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Canine Atopic Dermatitis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Canine Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Zoetis Opens New State-of-the-Art Facility in Lincoln, NE, USA
Zoetis conducted the opening of its state-of-the-art mAbs expansion facility in Lincoln, Nebraska, and the facility comprises manufacturing, testing, and support buildings, employing a dedicated workforce of nearly 950 employees who work around the clock year-round. The facility is responsible for the production of animal health biologics, biopharmaceuticals, and pharmaceutical products tailoring to meet the specific needs of animals. [Published On: 2023-08-09]
Zoetis Announces FDA Approval of Apoquel Chewable (oclacitinib chewable tablet) for Control of Pruritus Associated With Allergic Dermatitis and Control of Atopic Dermatitis in Dogs
Zoetis Inc. announced that the FDA approved Apoquel chewable tablet for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and above. This chewable treatment is the first of its kind in the U.S., offering comparable efficacy to the original Apoquel (oclacitinib tablet). [Published On: 2023-06-13]
ILC Therapeutics entered into a strategic R&D partnership with Dechra Pharmaceuticals
UK-based biotech company ILC Therapeutics announced a research and development partnership with Dechra Pharmaceuticals. The collaboration aims to develop ILC's Caniferon product to treat canine atopic dermatitis. This collaboration contributes to their existing pipeline and may lead to a full development program and can enable the effective development of an effective treatment for canine atopic dermatitis. [Published On: 2023-05-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Canine Atopic Dermatitis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Canine Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, AbbVie, Inc., Agrolabo SpA, Bimeda, Inc., Bioceltix JSC, Bioiberica S.A.U., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Deep Marine Collagen, Elanco Animal Health Incorporated, Farnam Companies, Inc., IDEXX Laboratories, Inc., Incyte Corporation, Kemin Industries, Inc., LEO Pharma A/S, Merck & Co. Inc., Natural Dog Company, Nextmune, Nippon Zenyaku Kogyo Co., Ltd., Novartis AG, Ourofino Animal Health, Pfizer Inc, Phibro Animal Health Corporation, Regeneron Pharmaceuticals, Inc, Saiba Animal Health AG, Toray Industries Inc., Vetoquinol S.A., Virbac Corporation, Zinpro Corporation, Zoetis Inc., and Zymox by Pet King Brands LLC.
Market Segmentation & Coverage